Литература

1. Баркаган, З. С. Геморрагические заболевания и синдромы / З. С. Баркаган. – М.: Медицина, 1980. – 366 с.

2. Баркаган, З. С. Диагностика и контролируемая терапия нарушений гемостаза / З. С. Баркаган, А. П. Момот. – Изд. 2-е доп. – М.: Ньюдиамед- АО, 2001. – 296 с.

3. Баркаган, З. С. Учение о тромбофилиях на современном этапе // Консилиум. – 2000. – № 6. – С. 61–65.

4. Кириенко, А. И. Консервативное лечение тромбофлебита поверхностных вен нижних конечностей/ А. И. Кириенко, В. М. Кошкин // Медико-фарм. вестник. – 1996. – № 5. – C. 2–6.

5. Момот, А. П. Патология гемостаза. Принципы и алгоритмы клинико-лабораторной диагностики / А. П. Момот. – СПб.: ФормаТ, 2006. – 208 с.

6. Салтыкова, Н. Б. Особенности клинических проявлений и принципы терапии больных врожденными тромбофилиями / Н. Б. Салтыкова, В. Д. Каргин // Ученые записки СПбГМУ им. акад. И. П. Павлова. – 2004. – Т. XI, № 3 (Приложение). – С. 62–68.

7. Шевела, А. И. Генотипирование при венозных тромбозах: pro et contra / А. И. Шевела, В. А. Егоров, К. С. Севостьянова и др. // Флебология. – 2008. – Т. 2, № 2. – C. 19–24.

8. Шевченко, О. П. Гипергомоцистеинемия и ее клиническое значение / О. П. Шевченко, Г. А. Олефриенко // Лаборатория. – 2002. – № 1. – C. 3–7.

9. Шмелева, В. М. Гипергомоцистеинемия и полиморфизм гена метилентетрагидрофолатредуктазы как фактор риска развития артериальных и венозных тромбозов и атеросклеротического поражения сосудов / В. М. Шмелева, С. Н. Ка- пустин, Н. Б. Салтыкова и др. // Тромбоз, гемо- стаз, реология. – 2001. – № 1 (5). – С. 144–145.

10. Bertina, R. M. Mutation in blood coagulation factor V associated with resistance to activated protein C / R. M. Bertina, B. P. Koeleman, T. Koster et al. // Nature. – 1994. – Vol. 369. – P. 64–67.

11. Booth, G. Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events / G. Booth, E. Wang // CMAJ. – 2000. – Vol. 163, № 1. – P. 21–29.

12. Brophy, J. The edpidemiology of acute myocardial infarction and ischemic heart disease in Canada: data from 1976 to 1991 / J. Brophy // Can. J. Cardiol. – 1997. – Vol. 13. – P. 74–478.

13. Cappuccio, F. Homocysteine levels in men and women of different ethnic and cultural background living in England / F. Cappuccio, R. Bell, I. Perry et al. // Atherosclerosis. – 2002. – Vol. 164, № 1. – P. 95–102.

14. Carprini, J. A. Thrombophilia testing in patients with venous thrombosis / J. A. Carprini, S. Goldshteyn et al. // Eur. J. Vasc. Endovasc. Surg. – 2005. – Vol. 30. – P. 550–555.

15. Castanon, M. M. Plasma homocysteine cutoff values for venous thrombosis / M. M. Castanon, A. M. Lauricella, L. Kordich et al. // Clin. Chem. Lab. Med. – 2007. – Vol. 45, № 2. – P. 232–236.

16. Cattaneo, M. Hyperhomocysteinemia, atherosclerosis and thrombosis / M. Cattaneo // Thromb. Haemost. – 1999. – Vol. 81. – P. 165–176.

17. Cattaneo, M. Interrelation of hyperhomocysteinemia, factor V Leiden, and risk of future venous thromboembolism / M. Cattaneo, M. L. Monzani, I. Martinelli et al. // Circulation. – 1998. – Vol. 97. – P. 295.

18. Couturaud, F. Methylentetrahydrofolate reductase C677T genotype and venous thromboembolic disease / F. Couturaud, E. Oger, J. H. Abalain et al. // Respiration. – 2000. – Vol. 67, № 6. – P. 657–661.

19. Dawson, S. J. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression / S. J. Dawson, B. Wiman, A. Hamsten et al. // J. Biol. Chem. – 1993. – Vol. 268, № 15. – P. 10739–10745.

20. Den Heijer, M. Hyperhomocysteinemia and venous thrombosis: a quantitative review / M. den Heijer, H. J. Blom, W. B. Gerrits et al. // Thromb. Haemost. – 1997. – Supplement. – P. 532.

21. Den Heijer, M. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis / M. den Heijer, T. Koster, H. J. Blom et al. // N. Engl. J. Med. – 1996. – Vol. 334. – P. 759–762.

22. Den Heijer, M. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? / M. den Heijer, H. J. Blom, W. B. Gerrits et al. // Lancet. – 1995. – Vol. 345. – P. 882–885.

23. De Stefano, V. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation / V. De Stefano, I. Martinelli, P. Mannuccio Mannucci et al. // N. Engl. J. Med. – 1999. – Vol. 341, № 11. – P. 801–806.

24. Ebbing, M. Mortality and cardiovascular events in patients treated with homocysteine-lowering B Vitamins after coronary angiography. A randomized controlled trial / M. Ebbing, Q. Bleie, P. Ueland et al. // JAMA. – 2008. – Vol. 300, № 7. – P. 795–804.

25. Eichinger, S. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene / S. Eichinger, E. Minar, M. Hirschl et al. // Thromb. Haemost. – 1999. – Vol. 81. – P. 14–17.

26. Eriksson, P. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction / P. Eriksson, B. Kallin, F. van 't Hooft et al. // Proc. Natl. Acad. Sci. U S A. – 1995. – Vol. 92, № 6. – P. 1851–1855.

27. Falcon, C. R. High prevalence of hyperhomocysteinemia in patients with juvenile venous thrombosis / C. R. Falcon, M. Cattaneo, D. Panzeri et al. // Arterioscler. Thromb. – 1994. – Vol. 14. – P. 1080–1083.

28. Harpel, P. C. Homocysteine and hemostasis: pathogenic mechanisms predisposing to thrombosis / P. C. Harpel, X. Zhang, W. Borth // J. Nutr. – 1996. – Vol. 126, № 4. – P. 1285–1289.

29. Kark, J. Nonfasting plasma total homocysteine level and mortality in middle–aged and elderly men and women in Jerusalem / J. Kark, J. Selhub, B. Adler et al. // Ann. Int. Med. – 1999. – Vol. 131, № 5. – P. 321–330.

30. Kluijtmans, L. A. J. A common 844ins68 insertion variant in the cystathionine-b – synthase gene / L. A. J. Kluijtmans, G. H. J. Boers, F. J. M. Trijbels et al. // Biochem. Mol. Med. – 1997. – Vol. 62. – P. 23–25.

31. Kyrle, P. A. Levels of prothrombin fragment F1+2 in patients with hyperhomocys-teinemia and a history of venous thromboembolism / P. A. Kyrle, A. Stumpflen, M. Hirschl et al. // Thromb. Haemost. – 1997. – Vol. 78, № 5. – P. 1327–1331.

32. Loscalo, J. The oxidant stress of hyperhomocyst(e)inemia / J. Loscalo // J. Clin. Invest. – 1996. – Vol. 98, № 1. – P. 5–7.

33. Maessen-Visch, M. B. The prevalence of factor V Leiden mutation in patients with leg ulcers and venous insufficiency / M. B. Maessen-Visch, K. Hamilyak, D. J. Tazelaar et al. // Arch. Dermatol. – 1999. – Vol. 135, № 1. – P. 41–44.

34. Mansilha, A. Genetic polymorphism and risk of recurrent depp venous thrombosis in young people: prospective cohort study / A. Mansilha, F. Araujo et al. // Eur. J. Endovasc. Surg. – 2005. – Vol. 30. – P. 545–549.

35. Marcucci, R. Tissue factor and homocysteine levels in ischemic heart disease are associated with angiogrphically documented clinical recurrences after coronary angioplasty / R. Marcucci, D. Prisco, T. Brunelli et al. // Thromb. Haemost. – 2000. – Vol. 83. – P. 826–832.

36. Markis, M. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia / M. Markis, F. E. Preston, N. J. Beauchamp et al. // Thromb. Haemost. – 1997. – Vol. 78, № 3. – P. 990–992.

37. Mayer, E. Homocysteine and coronary atherosclerosis / E. Mayer, D. Jacobsen, K. Robinson // J. Am. Coll. Cardiol. – 1996. – Vol. 27. – P. 517–527.

38. Millenson, M. M. Pathogenesis of venous thromboembolism // Disorders of Thrombosis; eds M. M. Millenson, K. A. Bauer, R. Hull, G. F. Pineo. – Philadelphia: W. B. Saunders, 1996. – P. 175–190.

39. Minami, R. Protein S deficiency in three patients with thrombosis / R. Minami, M. Urata, M. Kurihara et al. // Rinsho Ketsueki . – 2001. – Vol. 42, № 86. – P. 610–615.

40. Poort, S. R. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis / S. R. Poort, F. R. Rosendaal, P. H. Reitsma et al. // Blood. – 1996. – Vol. 88. – P. 3698–3703.

41. Reyes-Engel, A. Plasma homocysteine levels, C677T polymorphism of methylenetetrahydrofalate reductasa gene, plasma renin activity and cardiovascular risk / A. Reyes-Engel, M. Morel, F. Aranda et al. // Am. J. Hypertens. – 2002. – Vol. 14, № 4. – P. 154

42. Rosendaal, F. R. High levels of factor VIII and venous thrombosis / F. R. Rosendaal // Thromb. Haemost. – 2000. – Vol. 83. – P. 1–2.

43. Rosendaal, F. R. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance) / F. R. Rosendaal, T. Koster, J. P. Vandenbroucke et al. // Blood. – 1995. – Vol. 85. – P. 1504–1508.

44. Rosendaal, F. R. Geographic distribution of the 20210 G to A prothrombin variant / F. R. Rosendaal, C. J. Doggen, A. Zivelin et al. // Thromb. Haemost. – 1998. – Vol. 79. – P. 706–708.

45. Sam, R. C. The association between raised coagulation factor levels and venous thrombo-embolism / R. C. Sam, M. Wong, D. J. Adam et al. // Eur. J. Endovasc. Surg. – 2005. – Vol. 30. – P. 539–544.

46. Tripodi, A. Issues concerning the laboratory investigation of inherited thrombophilia / A. Tripodi // Mol. Diagn. – 2005. – Vol. 9, № 4. – P. 181–186.

47. Veerkamp, M. Plasma homocysteine in subjects with familial combined hyperlipidemia / M. Veerkamp, J. de Graaf, M. den Heijer et al. // Atherosclerosis. – 2003. – Vol. 166, № 1. – P. 111–117.

48. Wotherspoon, F. Homocysteine, endothelial dysfunction and oxidative stress in type 1 diabetes mellitus / F. Wotherspoon, D. Laight, K. Shaw et al. // Br. J. Diabetes Vasc. Dis. – 2003. – Vol. 3, № 5. – P. 334–340.

49. Zoller, B. Resistence to activated protein C as an additional risk factor in hereditary deficiency of protein S / B. Zoller, A. Berntsdotter, G. de Frutos et al. // Blood. – 1995. – Vol. 12. – P. 3518–3523.